Copyright
©The Author(s) 2020.
World J Clin Cases. Dec 26, 2020; 8(24): 6264-6273
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Table 4 Comparison of background factors, including the type and status of underlying disease, between the hepatitis B virus reactivation group and the nonreactivation group
| Reactivation (n = 44) | Nonreactivation (n = 894) | Fisher P value | |
| Age (75 yr or over) (%) | 27.2 | 23.5 | 0.3314 |
| Double cancer (%) | 25.0 | 21.8 | 0.3592 |
| Stage (3, 4) (%) | 77.2 | 72.4 | 0.2936 |
| HCC (%) | 20.9 | 8.8 | 0.0150 |
| Digestion and absorption organ (%) | 79.0 | 58.7 | 0.0051 |
| Bone marrow suppression (%) | 30.2 | 33.4 | 0.7293 |
- Citation: Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273
- URL: https://www.wjgnet.com/2307-8960/full/v8/i24/6264.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i24.6264